Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension

By sjmartinez • October 11, 2022

Didriksen H, Molberg Ø, Mehta A, Jordan S, Palchevskiy V, Fretheim H, Gude E, Ueland T, Brunborg C, Garen T, Midtvedt Ø, Andreassen AK, Lund-Johansen F, Distler O, Belperio J, Hoffmann-Vold AM. Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension. Front Immunol. 2022 Sep 23;13:991743. doi: 10.3389/fimmu.2022.991743. PMID: 36211384; PMCID: PMC9541617.

Tags: Anti-CCL21, CCL21, ELISA Enzyme-linked immunosorbent assay, Luminex (xMAP) method, Publications, pulmonary arteria hypertension, Pulmonary, Critical Care & Sleep Medicine, systemic sclerosis

Related Posts

Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer

Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JJH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan[...]

A survey of cystic fibrosis physicians’ views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor

Burdis N, Milinic T, Bartlett LE, Goss L, Tallarico E, Boyle A, Thaxton A, Turner GA, Benvenuto LJ, Faro A, Goss CH, Kapnadak SG, Ramos[...]

In-Hospital Mortality and Treatment in Patients With Acute Coronary Syndrome With and Without Standard Modifiable Cardiovascular Risk Factors: Findings From the CCC-ACS Project

Gong W, Yan Y, Liu J, Wang X, Zheng W, Que B, Ai H, Smith SC Jr, Fonarow GC, Morgan L, Zhao D, Ma C,[...]